VYNE receives Nasdaq extension to Feb 2023; pays Tay £850k for BETi compounds

VYNE Therapeutics Inc.

Nasdaq granted 180-day extension until Feb 27, 2023 to regain minimum $1.00 bid price for 10 consecutive days.
VYNE common stock transferred from Nasdaq Global Select to Capital Market, effective Aug 31, 2022.
VYNE paid Tay Therapeutics £850,000 after receipt of Oral BETi Compounds meeting specified molecular profile.
Company expects to exercise exclusive option on Oral BETi Compounds by end of 2022, before Feb 28, 2023 expiry.
If compliance not regained by Feb 27, 2023, Nasdaq will delist; VYNE may appeal or consider reverse stock split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.